Bioequivalence Study of Empagliflozin

2026-525434-33-00 Protocol 01-EMP-BIO-25 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 7 Apr 2026 · End 29 Apr 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 01-EMP-BIO-25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 32
Countries 1
Sites 1

Not applicable (submitted trial is a BE study in healthy participants)

Key facts

Sponsor
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18], Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
7 Apr 2026 → 29 Apr 2026
Decision date (initial)
2026-03-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Not applicable (submitted trial is a BE study in healthy participants)

VersionLevelCodeTermSystem organ class
28.0 PT 10067585 Type 2 diabetes mellitus 100000004861
20.0 PT 10007554 Cardiac failure 100000004849

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Tarchominskie Zaklady Farmaceutyczne Polfa S.A.

Sponsor organisation
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Address
Ul. Aleksandra Fleminga 2
City
Warsaw
Postcode
03-176
Country
Poland

Scientific contact point

Organisation
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Contact name
Ilona Łojszczyk

Public contact point

Organisation
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Contact name
Ilona Łojszczyk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 32 1
Rest of world 0

Investigational sites

Czechia

1 site · Ended
Quinta-Analytica s.r.o.
Clinic, Umelecka 305/1, Moravska Ostrava, Moravska Ostrava A Privoz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2026-04-07 2026-04-29 2026-04-07 2026-04-18

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-02-20 Czechia Acceptable
2026-03-10
2026-03-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-19 Czechia Acceptable
2026-03-10
2026-03-19